TL;DR: BPC-157 is a synthetic 15-amino-acid fragment derived from a gastric-protective protein, studied in animal and cell models for its apparent role in angiogenesis, growth-factor signaling, and tendon-fibroblast repair. The evidence base is entirely preclinical — no controlled human trials confirm safety or effectiveness, and it is not an approved medicine.
BPC-157, also known as Body Protection Compound-157, has become one of the most studied peptides in tissue-repair research. This guide explores what makes BPC-157 unique, how it is thought to work, and what the preclinical literature actually shows. Throughout, it is important to keep one framing in mind: the evidence base for BPC-157 is overwhelmingly preclinical — drawn from animal models and in-vitro cell studies — and should not be read as proof of any human outcome. New to this field? Our beginner’s guide to peptide research covers foundational concepts referenced throughout this article.
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide, meaning it is a chain of 15 amino acids. It is a partial sequence derived from a larger protective protein originally identified in human gastric juice. The sequence is:
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Because it is only a fragment rather than a naturally occurring full-length protein, BPC-157 is sometimes described as a “stable gastric pentadecapeptide.” Unlike many peptides that degrade quickly, laboratory work has reported that BPC-157 remains comparatively stable in gastric juice and does not require a carrier molecule for activity in the experimental systems where it has been tested. This relative robustness is one reason it has attracted sustained research attention.
Mechanism of Action
The exact mechanisms of BPC-157 are still being elucidated, and most of what is understood comes from animal and cell-culture studies rather than controlled human trials. Preclinical research points to several interconnected pathways:
Angiogenesis and the nitric-oxide system
A recurring theme in BPC-157 research is the promotion of angiogenesis — the formation of new blood vessels. In animal models, this has been associated with modulation of the nitric-oxide (NO) system, which governs vascular tone and blood flow to injured tissue. Improved local blood supply is a plausible contributor to the tissue-repair effects observed in these preclinical settings.
Growth-factor pathways
Studies suggest BPC-157 may interact with several growth-factor systems, including VEGF (vascular endothelial growth factor) and EGF (epidermal growth factor). Upregulation of these signals in animal wound models is thought to support the recruitment of cells and the vascularization needed for healing.
Tendon and ligament fibroblast activity
In-vitro work on tendon fibroblasts has reported that BPC-157 can influence cell survival, migration, and the FAK–paxillin signaling pathway involved in cytoskeletal reorganization. These cellular processes are central to how connective tissue repairs itself, which is why tendon-to-bone and ligament models feature prominently in the literature.
Taken together, these pathways describe plausible mechanisms observed in the laboratory — not established therapeutic actions in people.
Research Background and Key Findings
BPC-157 has been investigated across a range of preclinical tissue-repair contexts:
- Tendon and ligament healing — Rodent studies have examined accelerated healing of transected tendons and tendon-to-bone junctions.
- Gastrointestinal protection — Consistent with its gastric-juice origin, BPC-157 has been studied for protective effects on the intestinal lining and against NSAID-induced damage in animal models, an area that overlaps with other gut-focused research peptides such as KPV.
- Muscle and wound repair — Various models have looked at skin wounds, muscle injury, and post-injury recovery, alongside other repair-oriented peptides like GHK-Cu.
- Nerve and bone models — Emerging preliminary work has explored nerve and fracture healing.
The crucial caveat is consistent across all of these areas: large, well-controlled human clinical trials are lacking. The promising results reported to date come largely from animal and in-vitro systems, and outcomes in these models do not reliably translate to humans. For a side-by-side look at how BPC-157 compares with another widely studied repair peptide, see our BPC-157 vs TB-500 comparison.
Forms and Related Peptides
In research settings, BPC-157 is supplied as a lyophilized (freeze-dried) powder, commonly in 5mg and 10mg vial sizes. It is frequently studied alongside TB-500 (a thymosin beta-4 fragment), because the two are thought to act through complementary pathways — BPC-157 via growth-factor and NO signaling, TB-500 via actin regulation and cell migration. Researchers interested in the second compound often reference TB-500 5mg.
A pre-combined BPC-157 / TB-500 blend also exists for studies that examine the two peptides together in a single preparation. Researchers designing multi-compound protocols often consult our common peptide stacks overview for additional context.
Reconstitution and Handling Overview
Lyophilized BPC-157 must be reconstituted with bacteriostatic water before it can be used in laboratory work. Because concentration and handling directly affect the reliability of any experiment, careful, consistent technique matters. Our peptide reconstitution guide walks through calculating volumes, mixing gently to avoid degrading the peptide, and labeling vials. For technique considerations when administering to research models, see our injection best practices overview. Dosage-specific details are covered on the BPC-157 5mg and BPC-157 10mg pages.
Research Dosing Considerations
The figures below reflect ranges reported in the research literature and are provided for general educational context only. They are not human medical instructions and should not be interpreted as such.
| Route | Common Research Range | Frequency |
|---|---|---|
| Subcutaneous | 250–500 mcg | 1–2x daily |
| Intramuscular | 250–500 mcg | 1–2x daily |
Note: These are research protocols only. BPC-157 is not approved for human use.
Example only: a 5 mg vial reconstituted with 2 mL bacteriostatic water yields 2500 mcg/mL, so a 250 mcg draw = 0.10 mL = 10 units on a U-100 syringe. Not a human dosing instruction.
In practice, variables such as vial size, reconstitution volume, and the specific model under study all influence how a given research protocol is designed. Consistency and accurate record-keeping are far more important to reproducible research than any single “standard” number.
Storage and Stability
BPC-157 is considered one of the more forgiving peptides to store, but proper handling still preserves integrity:
- Lyophilized form: Can be stored for extended periods when frozen at −20°C, protected from light and moisture.
- Reconstituted: Should be refrigerated and generally used within about 4–6 weeks.
- Gastric stability: Unlike many peptides, BPC-157 has shown notable stability in acidic conditions in laboratory testing.
Avoid repeated freeze–thaw cycles, and always allow refrigerated material to reach a stable state before handling. For general handling principles that apply across many compounds, see our peptide storage guide.
Safety, Legality, and Research Disclaimers
BPC-157 is a research peptide, not an approved medicine. It has not received marketing authorization as a drug in major jurisdictions, and its regulatory status varies from country to country and may change over time. In some regions it is explicitly restricted. Anyone conducting research is responsible for confirming the current legal status in their jurisdiction and for following the guidelines of their institution’s ethics and biosafety oversight.
While reported adverse effects in preclinical studies have been minimal, the absence of large human safety trials means long-term human safety is genuinely unknown. Nothing here constitutes medical advice, and none of this material endorses human consumption.
Sourcing and Quality Verification for Research
Because peptide purity directly affects experimental validity, quality verification is essential when sourcing material for research. Generic best practices include:
- Third-party testing — Independent laboratory analysis (for example, HPLC for purity and mass spectrometry for identity) rather than seller claims alone.
- Certificate of Analysis (COA) — A batch-specific COA documenting purity, identity, and the testing methods used.
- Batch traceability — Clear lot numbers that connect the physical vial to its documentation, so results can be tied to a known batch.
These principles apply generally and are independent of any particular supplier. For a deeper look at reading these documents, see our guide to understanding peptide purity and COAs.
Frequently Asked Questions
Is BPC-157 approved for human use? No. BPC-157 is an investigational research compound and is not an approved medicine. It is intended for laboratory research purposes only.
What does “preclinical” mean for BPC-157? It means the current evidence comes from animal models and cell studies rather than large controlled human trials. Findings are promising in these systems but cannot be assumed to translate to people.
Why is BPC-157 studied together with TB-500? The two are thought to act through complementary pathways, so researchers often examine them side by side or in a combined preparation. See our comparison article for details.
How stable is BPC-157 compared with other peptides? Laboratory work suggests it is relatively stable, including in acidic conditions, which is part of why it has attracted so much research interest. Reconstituted material should still be refrigerated and used within a few weeks.
How should reconstituted BPC-157 be stored? Refrigerated, protected from light, and generally used within about 4–6 weeks. See the reconstitution guide for handling details.
Where can I read about dosing ranges? General research ranges are summarized above; product-specific context is on the 5mg and 10mg pages. These are not human dosing instructions.
Conclusion
BPC-157 represents an interesting area of peptide research with a unique gastric-juice origin, notable stability, and a substantial preclinical literature spanning tendon, ligament, gut, and wound-repair models. Its proposed mechanisms — angiogenesis, growth-factor and nitric-oxide signaling, and effects on tendon fibroblasts — are biologically plausible and consistently reported in animal and cell studies. What remains missing is the large-scale human evidence that would be needed to draw clinical conclusions. As research continues, scientists hope to better understand its mechanisms and potential applications.
Disclaimer: This information is for educational and research purposes only. Peptides are research chemicals not intended for human consumption.
References
- Sikiric P, et al. Review articles on the stable gastric pentadecapeptide BPC 157 and tissue healing (preclinical). Current Pharmaceutical Design / Journal of Physiology and Pharmacology.
- Chang CH, et al. Preclinical research on BPC-157 and tendon fibroblast survival, migration, and healing outcomes.